

DAWN

What is DAWN?

“DAWN” is an electronic system that automatically monitors the blood tests of all patients on the special medications that are used to treat your type of arthritis

What do I need to do?

Have regular blood tests as advised. This can be done at your local surgery or hospital, using the appropriate blood forms, which we will provide you with.

What happens to the blood results?

These are automatically entered on the “DAWN” system from the Pathology (blood test) department when you have your blood taken. If your blood test results do not fall within the normal range you and your GP will be contacted and you will be advised if any change in treatment is necessary, If you miss an appointment for a blood test, the system will recognise that and we will contact you to remind you.

How will my condition be monitored?

You will continue to be seen in the Rheumatology clinic once started on treatment. Your rheumatologist will decide how often you need to be seen. Once your condition is stable your care may be shared between your GP and us. In which case, we will continue to monitor your blood results on “DAWN” but you would not need to return to the clinic

routinely unless your arthritis becomes more active. If there is a change in your condition, please see your GP in the first instance who will then contact us. We can see you again in our clinic if your GP feels it is needed. You also have access to our advice line number:

Rheumatology Advice Line:
0118 322 6574

There is an answer phone. Please leave your message on this number. The answer phone messages are listened to on a regular basis. These messages will be responded to by a team of Rheumatology Specialist Nurses and Admin staff as appropriate.

Useful contacts

Arthritis Care www.arthritiscare.org.uk

National Rheumatoid Arthritis Society
www.rheumatoid.org.uk/

Visit the Trust website
www.royalberkshire.nhs.uk

This document can be made available in other languages and formats upon request.

Department of Rheumatology, Feb 2011
Revised: March 2019
Review due: March 2021